Clinical Research Directory
Browse clinical research sites, groups, and studies.
Ma-Spore ALL 2020 Study
Sponsor: National University Hospital, Singapore
Summary
The primary objective of this trial is to improve the overall survival rate of children and young adult with B-lineage acute lymphoblastic leukemia (B-ALL) in Singapore and Malaysia in the context of a multicenter cooperative trial using a risk-stratified therapy.
Official title: Ma-Spore ALL-Seq 2020: RNA-Seq and IgH/TCR-Seq to Improve Risk Assignment in Childhood, Adolescent and Young Adult Acute Lymphoblastic Leukaemia
Key Details
Gender
All
Age Range
Any - 40 Years
Study Type
INTERVENTIONAL
Enrollment
500
Start Date
2020-03-04
Completion Date
2030-03
Last Updated
2024-03-28
Healthy Volunteers
No
Conditions
Interventions
Prednisolone
Oral
Dexamethasone
Oral
Vincristine
Intravenous
Methotrexate
Oral/ intrathecal/intravenous/subcutaneous
L-Asparaginase
Intramuscular
Pegylated asparaginase
Intravenous
Erwinase
Optional for those allergic to E.coli/PEG L-asparaginase (intravenous)
Dasatinib
Indicated only for ALL with BCR::ABL1 /BCR::ABL1-like/ tyrosine kinase fusion positive (oral)
Imatinib
Indicated only for ALL with BCR::ABL1 /BCR::ABL1-like/ tyrosine kinase fusion positive (oral)
Cyclophosphamide
Intravenous
Cytarabine
Subcutaneous/ Intravenous
Mercaptopurine
Oral
Thioguanine
Oral
Rituximab
Intravenous
Doxorubicin
Intravenous
Fludarabine
Intravenous
Locations (3)
Subang Jaya Medical Centre
Kuala Lumpur, Malaysia
University Malaya Medical Centre
Kuala Lumpur, Malaysia
KK Women's and Children's Hospital
Singapore, Singapore